MediXall Group, Inc.

2023 Q3 Form 10-Q Financial Statement

#000107997324000912 Filed on June 20, 2024

View on sec.gov

Income Statement

Concept 2023 Q3 2022 Q3

Balance Sheet

Concept 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $9.670K $75.58K
YoY Change -87.21% -78.38%
Cash & Equivalents $9.667K $75.58K
Short-Term Investments
Other Short-Term Assets $3.484K $20.52K
YoY Change -83.02% -93.36%
Inventory
Prepaid Expenses $0.00
Receivables
Other Receivables
Total Short-Term Assets $13.15K $96.10K
YoY Change -86.32% -85.41%
LONG-TERM ASSETS
Property, Plant & Equipment $14.68K $21.76K
YoY Change -32.5% -93.86%
Goodwill
YoY Change
Intangibles $291.2K $432.0K
YoY Change -32.6%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $442.4K $924.6K
YoY Change -52.16% 14.52%
TOTAL ASSETS
Total Short-Term Assets $13.15K $96.10K
Total Long-Term Assets $442.4K $924.6K
Total Assets $455.5K $1.021M
YoY Change -55.38% -30.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.056M $1.655M
YoY Change 24.23% 59.53%
Accrued Expenses $0.00 $20.33K
YoY Change -100.0% -93.9%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $3.648M $2.017M
YoY Change 80.9%
Total Short-Term Liabilities $5.704M $3.692M
YoY Change 54.5% 169.36%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $244.8K
YoY Change -100.0%
Total Long-Term Liabilities $0.00 $244.8K
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.704M $3.692M
Total Long-Term Liabilities $0.00 $244.8K
Total Liabilities $5.704M $3.937M
YoY Change 44.89% 187.22%
SHAREHOLDERS EQUITY
Retained Earnings -$35.72M -$30.83M
YoY Change 15.87%
Common Stock $130.5K $116.9K
YoY Change 11.65%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.249M -$2.916M
YoY Change
Total Liabilities & Shareholders Equity $455.5K $1.021M
YoY Change -55.38% -30.38%

Cashflow Statement

Concept 2023 Q3 2022 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
34748
dei City Area Code
CityAreaCode
800
dei Local Phone Number
LocalPhoneNumber
381-1787
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
159755335 shares
CY2023Q3 us-gaap Cash
Cash
9667 usd
CY2022Q4 us-gaap Cash
Cash
3416 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
3484 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
8083 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
13151 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
11499 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14684 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21755 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0 usd
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
291166 usd
CY2022Q4 mdxl Accounts Payable Related Parties Currents
AccountsPayableRelatedPartiesCurrents
610290 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
75691 usd
CY2023Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
106443 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
166167 usd
CY2023Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
3648015 usd
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2555793 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5704356 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4341921 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
189457 usd
us-gaap Revenues
Revenues
214925 usd
us-gaap Revenues
Revenues
39025 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
63110 usd
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2022Q3 mdxl Professional Fees Related Party
ProfessionalFeesRelatedParty
50100 usd
mdxl Professional Fees Related Party
ProfessionalFeesRelatedParty
0 usd
mdxl Professional Fees Related Party
ProfessionalFeesRelatedParty
227600 usd
CY2023Q3 mdxl Management Fee Related Party
ManagementFeeRelatedParty
0 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
2587035 usd
CY2023Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
191358 usd
CY2022Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
313510 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001601280
CY2023Q2 mdxl Conversion Of Shares From Preferred Stock To Common Stock
ConversionOfSharesFromPreferredStockToCommonStock
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-194337
dei Entity Registrant Name
EntityRegistrantName
MediXall Group, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0864127
dei Entity Address Address Line1
EntityAddressAddressLine1
104 N
dei Entity Address Address Line2
EntityAddressAddressLine2
4th Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Leesburg
CY2023Q3 mdxl Intellectual Property
IntellectualProperty
136500 usd
CY2022Q4 mdxl Intellectual Property
IntellectualProperty
156000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
260177 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
412582 usd
CY2023Q3 us-gaap Assets
Assets
455501 usd
CY2022Q4 us-gaap Assets
Assets
862013 usd
CY2023Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1446051 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1100147 usd
CY2023Q3 mdxl Accounts Payable Related Parties Currents
AccountsPayableRelatedPartiesCurrents
610290 usd
CY2023Q3 us-gaap Liabilities
Liabilities
5704356 usd
CY2022Q4 us-gaap Liabilities
Liabilities
4531378 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130487491 shares
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130487491 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
122187491 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
122187491 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
130487 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
122182 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
30338317 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
28817084 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35721745 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32612805 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5248855 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3669365 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
455501 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
862013 usd
CY2023Q3 us-gaap Revenues
Revenues
65535 usd
CY2022Q3 us-gaap Revenues
Revenues
20766 usd
us-gaap Cost Of Revenue
CostOfRevenue
188096 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
2425 usd
CY2022Q3 us-gaap Gross Profit
GrossProfit
20766 usd
us-gaap Gross Profit
GrossProfit
26829 usd
us-gaap Gross Profit
GrossProfit
39025 usd
CY2023Q3 us-gaap Professional Fees
ProfessionalFees
519787 usd
CY2022Q3 us-gaap Professional Fees
ProfessionalFees
227914 usd
us-gaap Professional Fees
ProfessionalFees
1630894 usd
us-gaap Professional Fees
ProfessionalFees
824527 usd
CY2023Q3 mdxl Professional Fees Related Party
ProfessionalFeesRelatedParty
0 usd
CY2022Q3 mdxl Management Fee Related Party
ManagementFeeRelatedParty
240000 usd
mdxl Management Fee Related Party
ManagementFeeRelatedParty
0 usd
mdxl Management Fee Related Party
ManagementFeeRelatedParty
720000 usd
CY2023Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
162345 usd
CY2022Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
273120 usd
us-gaap Labor And Related Expense
LaborAndRelatedExpense
649593 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
683445 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
727837 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
37002 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
0 usd
us-gaap Interest Expense
InterestExpense
171837 usd
us-gaap Interest Expense
InterestExpense
0 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
910492 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
1104644 usd
us-gaap Operating Expenses
OperatingExpenses
3135769 usd
us-gaap Operating Expenses
OperatingExpenses
5086999 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-908067 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1083878 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3108940 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5047974 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-908067 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1083878 usd
us-gaap Net Income Loss
NetIncomeLoss
-3108940 usd
us-gaap Net Income Loss
NetIncomeLoss
-5047974 usd
CY2023Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
78996 usd
CY2022Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
78995 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
234410 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
234410 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-987063 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1162873 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3343350 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5282384 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130487491 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
130487491 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116886659 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116886659 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126048154 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126048154 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115896191 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115896191 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-340122 usd
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
720000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1094929 usd
CY2022Q1 mdxl Common Stock Issued In Exchange For Righttouse Intellectual Property
CommonStockIssuedInExchangeForRighttouseIntellectualProperty
236000 usd
CY2022Q1 mdxl Stock Issued During Period Value Debentures
StockIssuedDuringPeriodValueDebentures
23800 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2410102 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-675495 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
40500 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
365398 usd
CY2022Q2 mdxl Stock Issued During Period Value Debentures
StockIssuedDuringPeriodValueDebentures
59146 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-1553994 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-1764445 usd
CY2022Q3 mdxl Stock Issued During Period Value Debentures
StockIssuedDuringPeriodValueDebentures
174750 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
72800 usd
CY2022Q3 us-gaap Stock Repurchased And Retired During Period Value
StockRepurchasedAndRetiredDuringPeriodValue
-315500 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1083878 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-2916273 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-3669365 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
467980 usd
CY2023Q1 mdxl Common Stock Issued Value
CommonStockIssuedValue
1853 usd
CY2023Q1 mdxl Stock Issued During Period Value Debentures
StockIssuedDuringPeriodValueDebentures
48525 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1221495 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-4372502 usd
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
467982 usd
CY2023Q2 mdxl Stock Issued During Period Value Debentures
StockIssuedDuringPeriodValueDebentures
45781 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-979378 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-4838117 usd
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
467982 usd
CY2023Q3 mdxl Stock Issued During Period Value Debentures
StockIssuedDuringPeriodValueDebentures
29347 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-908067 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-5248855 usd
us-gaap Net Income Loss
NetIncomeLoss
-3108940 usd
us-gaap Net Income Loss
NetIncomeLoss
-5047974 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7071 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1621 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1403944 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1217627 usd
mdxl Amortization Of Debenture Discounts
AmortizationOfDebentureDiscounts
183377 usd
mdxl Amortization Of Debenture Discounts
AmortizationOfDebentureDiscounts
59781 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-4599 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
17040 usd
mdxl Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
0 usd
mdxl Increase Decrease In Prepaid Expenses Related Party
IncreaseDecreaseInPrepaidExpensesRelatedParty
276043 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
345904 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
257638 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
0 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
241608 usd
mdxl Net Change In Rightofuse Operating Lease Asset And Liability
NetChangeInRightofuseOperatingLeaseAssetAndLiability
-4971 usd
mdxl Net Change In Rightofuse Operating Lease Asset And Liability
NetChangeInRightofuseOperatingLeaseAssetAndLiability
3196 usd
mdxl Increase Decrease In Amortization Of Intellectual Property
IncreaseDecreaseInAmortizationOfIntellectualProperty
19500 usd
mdxl Increase Decrease In Amortization Of Intellectual Property
IncreaseDecreaseInAmortizationOfIntellectualProperty
25287 usd
mdxl Increase Decrease In Amortization Of Website And Development
IncreaseDecreaseInAmortizationOfWebsiteAndDevelopment
121416 usd
mdxl Increase Decrease In Amortization Of Website And Development
IncreaseDecreaseInAmortizationOfWebsiteAndDevelopment
19411 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1028100 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2962802 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1853 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
760500 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1032498 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2214462 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1034351 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2974962 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
6251 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
12160 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3416 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63418 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9667 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75578 usd
mdxl Issuance Of Common Stock In Exchange For Intellectual Property
IssuanceOfCommonStockInExchangeForIntellectualProperty
0 usd
mdxl Issuance Of Common Stock In Exchange For Intellectual Property
IssuanceOfCommonStockInExchangeForIntellectualProperty
236000 usd
mdxl Discount Issued With Convertible Debentures
DiscountIssuedWithConvertibleDebentures
123653 usd
mdxl Discount Issued With Convertible Debentures
DiscountIssuedWithConvertibleDebentures
257695 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
mdxl Retirement Of Common Shares Issued For Services
RetirementOfCommonSharesIssuedForServices
0 usd
mdxl Retirement Of Common Shares Issued For Services
RetirementOfCommonSharesIssuedForServices
315500 usd
CY2023Q3 us-gaap Revenues
Revenues
65535 usd
CY2022Q3 us-gaap Revenues
Revenues
20766 usd
us-gaap Revenues
Revenues
214925 usd
us-gaap Revenues
Revenues
39025 usd
mdxl Decrease In Net Loss
DecreaseInNetLoss
1900000 usd
mdxl Decrease In Net Loss
DecreaseInNetLoss
1900000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3108940 usd
us-gaap Net Income Loss
NetIncomeLoss
-5047974 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-35721745 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84E_eus-gaap--UseOfEstimates_zDOzn1JofTYi" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><i><span id="xdx_860_zLLrSb7A2tT2">Use of Estimates</span></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0; text-align: justify; text-indent: 0.5in">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.55pt 0 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0; text-align: justify; text-indent: 0.5in">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the condensed consolidated financial statements, which management considered in formulating its estimate could change in the near term due to one or more future non-conforming events. Accordingly, the actual results could differ significantly from estimates.</p> <p style="font: 9.5pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0; text-align: justify; text-indent: 0.5in">A material estimate that is particularly susceptible to significant change in the near-term relate to the determination of the impairment of website and development cost and intellectual property. The Company uses various assumptions it believes to be reasonable under the circumstances to make this estimate. Although considerable variability is likely to be inherent in this estimate, management believes that the amount provided is reasonable. This estimate is continually reviewed and adjusted if necessary. Such adjustments are reflected in current operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
78996 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zhRQYsQdzPC" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 12pt"><i><span id="xdx_86B_zvuVRVB7CFJ6">Risks and Uncertainties</span> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0; text-align: justify; text-indent: 0.5in">The Company's operations are subject to significant risks and uncertainties including financial, operational, and regulatory risks, including the potential risk of business failure.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0.5pt 0 0; text-align: justify; text-indent: 0.5in"> </p>
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-908067 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-1083878 usd
us-gaap Net Income Loss
NetIncomeLoss
-3108940 usd
us-gaap Net Income Loss
NetIncomeLoss
-5047974 usd
CY2022Q3 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
78995 usd
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
234410 usd
us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
234410 usd
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-987063 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1162873 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3343350 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-5282384 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130487491 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
130487491 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116886659 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116886659 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126048154 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126048154 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115896191 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115896191 shares
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
156000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-19500 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
136500 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
6500 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
26000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
26000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
26000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
26000 usd
CY2023Q3 mdxl Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
26000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
136500 usd
mdxl Securities Purchase Agreement Description
SecuritiesPurchaseAgreementDescription
In March 2022, the Company entered into a securities purchase agreement in which the Company maximum offering amount is $5,000,000. For every $1,000 invested in the offering, the Investors will receive a Debenture with a face amount of $1,000 and Warrants to purchase 350 Common Shares at an exercise price that ranges from $0.75 to $1.50 per share expiring on April 30, 2027.
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1274687 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
0.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2023Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
123653 usd
CY2023Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
64172 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
183377 usd
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
2555793 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1032498 usd
mdxl Relative Fair Value Of Warrants Issued As Discount
RelativeFairValueOfWarrantsIssuedAsDiscount
-123653 usd
mdxl Accretion Of Warrants Issued As Discount
AccretionOfWarrantsIssuedAsDiscount
183377 usd
CY2023Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
3648015 usd
CY2023Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001079973-24-000912-index-headers.html Edgar Link pending
0001079973-24-000912-index.html Edgar Link pending
0001079973-24-000912.txt Edgar Link pending
0001079973-24-000912-xbrl.zip Edgar Link pending
ex31x1.htm Edgar Link pending
ex31x2.htm Edgar Link pending
ex32x1.htm Edgar Link pending
ex32x2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
mdxl-20230930.xsd Edgar Link pending
mdxl_10q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mdxl-20230930_cal.xml Edgar Link unprocessable
mdxl-20230930_def.xml Edgar Link unprocessable
mdxl_10q_htm.xml Edgar Link completed
mdxl-20230930_pre.xml Edgar Link unprocessable
mdxl-20230930_lab.xml Edgar Link unprocessable